Abstract

Although there are considerable data on the use of mathematical modeling to describe tumor growth and response to therapy, previous approaches are often not of the form that can be easily applied to clinical data to generate testable predictions in individual patients. Thus, there is a clear need to develop and apply clinically relevant oncologic models that are amenable to available patient data and yet retain the most salient features of response prediction. In this study we show how a biomechanical model of tumor growth can be initialized and constrained by serial patient-specific magnetic resonance imaging data, obtained at two time points early in the course of therapy (before initiation and following one cycle of therapy), to predict the response for individual patients with breast cancer undergoing neoadjuvant therapy. Using our mechanics coupled modeling approach, we are able to predict, after the first cycle of therapy, breast cancer patients that would eventually achieve a complete pathologic response and those who would not, with receiver operating characteristic area under the curve (AUC) of 0.87, sensitivity of 92%, and specificity of 84%. Our approach significantly outperformed the AUCs achieved by standard (i.e., not mechanically coupled) reaction–diffusion predictive modeling (0.73), simple analysis of the tumor cellularity estimated from imaging data (0.73), and the Response Evaluation Criteria in Solid Tumors (0.71). Thus, we show the potential for mathematical model prediction for use as a prognostic indicator of response to therapy. The work indicates the considerable promise of image-driven biophysical modeling for predictive frameworks within therapeutic applications.

Major Findings

Using a mathematical model based on basic tissue mechanical properties and constrained by patient-specific imaging data can provide predictions of outcome that outperform conventional RECIST-based approaches.

Introduction

Neoadjuvant therapy is often administered to patients with locally advanced breast cancer in order to reduce the tumor burden prior to surgery (10). Patients exhibiting pathologic complete response (pCR; defined as no residual viable tumor on histologic analysis in breast or nodes at the completion of therapy) demonstrate significantly enhanced disease-free progression/survival; thus, this metric has emerged as the gold standard for evaluating response to neoadjuvant therapy (11, 12). With numerous neoadjuvant therapy regimens available, and many more treatments emerging, reliable prediction of patients that will go on to achieve pCR is highly significant. If accurate predictions that the regimen is not effective can be made early in a patient’s treatment, the treatment could be changed to another, potentially more effective approach, thereby avoiding unnecessary treatment-related toxicities and providing a greater chance of achieving pCR (13).

Assessing early treatment response with the goal of predicting pCR remains a challenging clinical problem with no current uniform approach. Because of their quantitative and noninvasive nature, imaging-based biomarkers are attractive surrogate metrics for response assessment. Several imaging-based metrics have been investigated as biomarkers for predicting response in the neoadjuvant setting (14–22), with many efforts focusing on monitoring changes in morphologic characteristics. However, morphology-based characteristics are downstream from the underlying treatment-induced biologic response, and are, therefore, indicative only of late stage response. More recent efforts have focused on using functional parameters available from quantitative magnetic...
Our modeling approach uses serial diffusion weighted magnetic resonance imaging (DW-MRI) data of tumor cellularity obtained before and after the first cycle of neoadjuvant therapy to generate spatial estimates of tumor cell proliferation/death in response to therapy. Because of the timing of data acquisition, the estimated spatial proliferation term is based on measured changes in cell density with treatment and therefore represents the net difference between cell growth and death. To separately estimate cell growth and death rates independently, additional data would be required. We assume a constant antitumor effect in time during therapy, and use our estimates of proliferation/death to run the model forward in time to predict the residual tumor burden at the conclusion of therapy. DW-MRI data sets are fit to Eq. A to return apparent diffusion coefficient (ADC) values on a voxel-by-voxel basis:

\[
ADC = \frac{\sum_{i=x,y,z} \ln(S_0/S_i)/b_i}{3},
\]

where \(i\) is the direction of diffusion weighting, \(b_i\) is the amount of diffusion weighting imparted to the sample, \(S_0\) denotes the signal intensity in the absence of diffusion gradients, and \(S_i\) is the signal intensity in the presence of the diffusion-sensitizing gradient. Using Eq. B, the ADC data for voxels satisfying the dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) threshold criteria of 80% enhancement (1) were transformed to an estimate of tumor cell number, \(N(\hat{x}, t)\):

\[
N(\hat{x}, t) = \theta \left( \frac{ADC_{sp} - ADC(\hat{x}, t)}{ADC_{max} - ADC_{min}} \right),
\]

where \(\theta\) is the carrying capacity (i.e., the total number of tumor cells that fit within a voxel), \(ADC_{sp}\) is the ADC of free water at \(37^\circ C (3 \times 10^{-3} \text{ mm}^2/\text{s})\), \(ADC(\hat{x}, t)\) is the ADC value at position \((\hat{x}, \hat{y})\) in image space, and \(ADC_{max}\) is the minimum ADC value measured within the tumor for each patient, which corresponds to the voxel with the largest number of cells. The carrying capacity, \(\theta\), was calculated as the ratio of the imaging voxel volume to the assumed tumor cell volume, assuming spherical tumor cells with packing density of 0.7405 (2) and a nominal tumor cell radius of 10 \(\mu\text{m}\) (tumor cell volume of 4189 \(\mu\text{m}^3\)). Details of this approach are provided in refs. 3 and 4.

The set of coupled, partial differential equations governing the tumor growth model is shown in Eqs. C–E:

\[
\frac{\partial N(x, t)}{\partial t} = \nabla \cdot \left( D \nabla N(x, t) + k_N N(x, t) \left( 1 - \frac{N(x, t)}{\theta} \right) \right),
\]

\[
D = D_0 e^{-\gamma \sigma_{\text{VMM}}(x,t)},
\]

\[
\nabla \cdot G \nabla u + \nabla \left( \frac{G}{1 - 2\nu} (\nabla \cdot u) - \lambda \nabla N(x, t) \right) = 0.
\]

Equation C models the spatiotemporal rate of change of tumor cell number as the sum of random cell diffusion and logistic growth. The apparent cell diffusion term, \(D\), is linked to surrounding tissue mechanics via Eq. D, where \(\sigma_{\text{VMM}}\) is the von Mises stress, \(\gamma\) is an empirically derived coupling constant, and \(D_0\) is the diffusion of tumor cells in the absence of external stress (5). Eq. E defines linear elastic, isotropic mechanical equilibrium subject to an external expansive force determined by changes in tumor cell number, \(N(x, t)\), and a coupling constant \(\lambda\). This equation governs the response of the displacement vector, \(u\), to tumor cell growth. \(G\) represents shear modulus, an intrinsic mechanical property of breast and tumor tissue.

In this model, a growing tumor imparts an external force on the surrounding tissue, which induces tissue deformation. This "mass effect" is the phenomenon by which a growing tumor displaces surrounding tissue. The overall deformation serves to increase the total mechanical distortion energy of the tissue, which depends on the local tissue mechanical properties of the immediately surrounding tissue (breast fibroglandular tissue is typically reported to be twice as stiff as adipose tissue; ref. 6). As tumors have been shown to be sensitive to their mechanical microenvironment, exhibiting reduced outward growth/expansion in areas of high stress (7, 8), accumulated distortion energy serves to inhibit tumor invasiveness in our model through a mechano-inhibitory reduction in the apparent tumor cell diffusion coefficient, \(D\). More details of the model implementation are provided in ref. 9.

We acquire DW-MRI data at two time points, prior to initiating therapy and after one cycle of therapy, and use Eq. A to calculate ADC values. These serial ADC maps are then transformed to estimate the tumor cell density distribution at each time point using Eq. B. We then fit these data to a model of tumor growth/response, Eqs. C–E, to yield estimates of tumor cell proliferation/death and diffusion. The estimated parameters are then used in conjunction with the model to predict, by projecting the model forward in time, the residual tumor burden at the conclusion of neoadjuvant therapy.

Major assumptions in our modeling approach include a reduction in dimensionality to two-dimensional analysis of central-slice MR data, constant proliferation/diffusion values throughout neoadjuvant therapy following initial parameter estimation, and the nature of the mechano-inhibitory effect on tumor cell diffusivity. We return to these important assumptions in the Discussion.
neutron imaging (MRI) techniques. For example, in the recent multi-site American College of Radiology Imaging Network (ACRIN) 6657 Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis (I-SPY TRIAL) (22), Hylton and colleagues examined traditional clinical assessment combined with imaging morphologic measurements and contrast enhanced signal enhancement ratio (SER). A four-predictor multivariate statistical model (clinical size, longest diameter, volume, and SER) was shown to have receiver operator characteristic (ROC) area under the curve (AUC) of 0.73 for prediction of pCR at an early imaging time point, prior to the second cycle of neoadjuvant therapy. A preliminary extension of this approach to combine quantitative region of interest (ROI) and voxel-level analysis metrics from both dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI, efflux rate transfer constant ($k_{ep}$), and apparent diffusion coefficient (ADC), respectively, in a multivariate regression statistical analysis showed promise for achieving a higher predictive ability, with AUC for pCR prediction of 0.87 at an early imaging time point, after the first cycle of neoadjuvant therapy (17). These studies extract a single parameter or sets of parameters from quantitative imaging data analysis and perform a statistical correlation to clinical outcomes. However, the physiologic interpretation of statistical combinations of extracted parameters as they pertain to pCR or reduction in tumor burden is often largely unknown.

One promising way to maximize the impact of quantitative noninvasive imaging data is to use mathematical models of tumor growth driven by early time point imaging data in order to determine and predict therapeutic response. Major advances in mathematical modeling of tumor growth have occurred, where sophisticated simulations can be generated that recapitulate many cellular and bulk-level aspects of tumor growth and treatment response (23–25). Unfortunately, many such models are fundamentally limited in that they cannot readily incorporate clinical data and require knowledge of many different parameters of tumor growth/status that are either impractical or impossible to measure clinically (e.g., immune response, extracellular matrix status, genetic mutations, etc.). As complex, multiparametric models often require an extensive array of model parameters either obtained from literature values or empirically derived, they cannot be practically applied to individual patients. Thus, the field of mathematical oncology has been limited to more fundamental investigations and patient-specific predictive modeling has only seen limited clinical application. There is a clear need to develop clinically relevant oncological models that are amenable to available patient data and yet retain the most salient features of response prediction (13).

We and others (4, 26–31) have recently suggested using quantitative in vivo imaging data to drive mathematical models of tumor growth for predicting response. Following parameterization, these models can then be projected forward in space and time to predict eventual tumor distribution outcomes on a patient-specific basis. Rather than taking a classical reductionist approach where each appropriate physiologic constituent tumor-associated process is described mathematically and coupled into a comprehensive, yet increasingly complex representation, we have chosen to begin with a more traditional spatiotemporal growth model framework and allow readily available clinical imaging data to guide the determination of model parameters in a best-fit sense. The goal of this study is to determine if a patient-specific mechanically coupled reaction–diffusion model of tumor response to therapy can be used as a predictive indicator of pCR.

Materials and Methods

Subject description

An existing database of patients with breast cancer receiving quantitative MRI before ($t_1$), after one cycle ($t_2$), and at the conclusion ($t_3$) of neoadjuvant therapy from a previous study (17) was utilized for this retrospective analysis. Briefly, 33 patients with stage II/III breast cancer who underwent neoadjuvant therapy as a component of their clinical care were selected for this study. Inclusion criteria were as follows: no prior systemic therapies for breast cancer and histologically documented invasive carcinoma of the breast with a sufficient risk of recurrence, based on pretreatment clinical parameters of size, grade, age, and nodal status, to warrant the use of neoadjuvant therapy. Neoadjuvant therapy was administered at the discretion of the treating medical oncologist based on pretreatment clinical parameters.

Tumor type was classified based on expression status for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) and categorized as ER and/or PR positive, HER2 positive, or triple-negative (ER, PR, and HER2 negative): see Table 1. Most patients with HER2 positive tumors received paclitaxel, carboplatin, and trastuzumab every 2 weeks for four cycles followed by 12 weekly cycles of paclitaxel. Most patients with triple-negative tumors participated in an ongoing clinical trial and received weekly cisplatin and paclitaxel with or without everolimus for 12 weeks. Response status was determined at the time of surgery by a pathologist as either pCR, which is defined as no residual viable tumor on histologic analysis of the breast or nodes at the completion of neoadjuvant therapy, or non-pCR, which designates any residual invasive tumor on histologic analysis in breast or...
nodes at the completion of neoadjuvant therapy. Participating patients provided informed written consent to an Institutional Review Board approved study. For more information on the patient population, the reader is referred to Li and colleagues (17).

Data acquisition

MRI was performed using a Philips 3T Achieva MR scanner (Philips Healthcare). A four-channel receive double-breast coil was used for 13 patients. thrive (7), high-resolution isotropic volume examination) anatomical data were acquired via a 400 × 400 × 129 acquisition matrix over a 20 cm × 20 cm × 12.9 cm transverse field of view (FOV) with one signal acquisition, and TR/TE/α = 6.43 ms/3.4 ms/10°. Dynamic contrast enhanced MRI (DCE-MRI) utilized an acquisition matrix of 192 × 192 × 20 (full breast) over a sagittal square FOV (22 cm × 22 cm) with slice thickness of 5 mm, one signal acquisition, and a SENSE factor of 2. Dynamic scans used a flip angle of 20°. Each dynamic set was collected in 16 s at 25 time points. A catheter placed within an antecubital vein delivered 0.1 mmol/kg (9–15 mL, depending on patient weight) of gadopentetate dimeglumine, Gd-DTPA (Magnevist) at 2 mL/s, followed by a saline flush, via a power injector (Medrad) after the acquisition of three baseline dynamic scans. DCE-MRI data were longitudinally coregistered (32) across all time points. Central-slice images through the midpoint of the tumor were extracted from MRI volumes for further analysis. DCE-MRI data were used to define a tumor region-of-interest for voxels satisfying 80% signal enhancement threshold (9) between the precontrast images (i.e., the average signal intensity from DCE-MRI time points 1–3) and the postcontrast images (i.e., the average signal intensity from DCE-MRI time points 4–25). Voxels that showed a signal intensity increase more than the 80% threshold between the pre- and postcontrast data were defined as tumor (1). ADC maps were calculated from DW-MRI datasets using Eq. A

---

### Table 1. Patient and tumor characteristics of the study population

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age (years)</th>
<th>Tumor type</th>
<th>Tumor grade</th>
<th>Pathologic response</th>
<th>Days between $t_1$ and $t_2$</th>
<th>Therapeutic regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>50</td>
<td>ER$^+$ and/or PR$^+$</td>
<td>3</td>
<td>Non-pCR</td>
<td>14</td>
<td>AC–Taxol</td>
</tr>
<tr>
<td>2</td>
<td>52</td>
<td>HER2$^+$</td>
<td>3</td>
<td>Non-pCR</td>
<td>18</td>
<td>Taxotere</td>
</tr>
<tr>
<td>3</td>
<td>60</td>
<td>HER2$^+$</td>
<td>1</td>
<td>Non-pCR</td>
<td>13</td>
<td>AC–Taxol + concurent trastuzumab</td>
</tr>
<tr>
<td>4</td>
<td>36</td>
<td>Triple negative</td>
<td>2</td>
<td>Non-pCR</td>
<td>7</td>
<td>Taxol + cisplatin ± everolimus</td>
</tr>
<tr>
<td>5</td>
<td>48</td>
<td>ER$^+$ and/or PR$^+$</td>
<td>1</td>
<td>Non-pCR</td>
<td>14</td>
<td>Dose-dense AC–Taxol</td>
</tr>
<tr>
<td>6</td>
<td>43</td>
<td>ER$^+$ and/or PR$^+$</td>
<td>2</td>
<td>Non-pCR</td>
<td>14</td>
<td>Dose-dense AC–Taxol</td>
</tr>
<tr>
<td>7</td>
<td>59</td>
<td>ER$^+$ and/or PR$^+$</td>
<td>2</td>
<td>Non-pCR</td>
<td>28</td>
<td>Dose-dense AC–Taxol</td>
</tr>
<tr>
<td>8</td>
<td>53</td>
<td>Triple negative</td>
<td>2</td>
<td>Non-pCR</td>
<td>9</td>
<td>Taxol + cisplatin ± everolimus</td>
</tr>
<tr>
<td>9</td>
<td>55</td>
<td>HER2$^+$</td>
<td>3</td>
<td>Non-pCR</td>
<td>25</td>
<td>Trastuzumab + carboplatin + ixabepilone</td>
</tr>
<tr>
<td>10</td>
<td>28</td>
<td>Triple negative</td>
<td>3</td>
<td>Non-pCR</td>
<td>9</td>
<td>Taxol + cisplatin ± everolimus</td>
</tr>
<tr>
<td>11</td>
<td>33</td>
<td>ER$^+$ and/or PR$^+$</td>
<td>3</td>
<td>Non-pCR</td>
<td>9</td>
<td>AC–Taxol</td>
</tr>
<tr>
<td>12</td>
<td>39</td>
<td>ER$^+$ and/or PR$^+$</td>
<td>1</td>
<td>Non-pCR</td>
<td>13</td>
<td>AC–Taxol</td>
</tr>
<tr>
<td>13</td>
<td>57</td>
<td>Triple negative</td>
<td>3</td>
<td>Non-pCR</td>
<td>13</td>
<td>AC–Taxol</td>
</tr>
<tr>
<td>14</td>
<td>67</td>
<td>HER2$^+$</td>
<td>3</td>
<td>Non-pCR</td>
<td>11</td>
<td>Dose-dense AC–Taxol</td>
</tr>
<tr>
<td>15</td>
<td>45</td>
<td>Triple negative</td>
<td>3</td>
<td>Non-pCR</td>
<td>17</td>
<td>Taxol + cisplatin ± everolimus</td>
</tr>
<tr>
<td>16</td>
<td>46</td>
<td>HER2$^+$</td>
<td>3</td>
<td>Non-pCR</td>
<td>19</td>
<td>Taxotere + carboplatin + Herceptin</td>
</tr>
<tr>
<td>17</td>
<td>47</td>
<td>ER$^+$ and/or PR$^+$</td>
<td>1</td>
<td>Non-pCR</td>
<td>17</td>
<td>Taxotere–AC</td>
</tr>
<tr>
<td>18</td>
<td>36</td>
<td>HER2$^+$</td>
<td>2</td>
<td>Non-pCR</td>
<td>15</td>
<td>AC–Taxol</td>
</tr>
<tr>
<td>19</td>
<td>43</td>
<td>HER2$^+$</td>
<td>3</td>
<td>Non-pCR</td>
<td>7</td>
<td>Cisplatin + Taxol ± everolimus</td>
</tr>
<tr>
<td>20</td>
<td>55</td>
<td>ER$^+$ and/or PR$^+$</td>
<td>2</td>
<td>Non-pCR</td>
<td>24</td>
<td>AC–Taxol</td>
</tr>
<tr>
<td>21</td>
<td>58</td>
<td>ER$^+$ and/or PR$^+$</td>
<td>2</td>
<td>Non-pCR</td>
<td>7</td>
<td>Cisplatin + Taxol ± everolimus</td>
</tr>
<tr>
<td>22</td>
<td>53</td>
<td>HER2$^+$</td>
<td>3</td>
<td>pCR</td>
<td>21</td>
<td>AC–concurent Taxol + trastuzumab</td>
</tr>
<tr>
<td>23</td>
<td>46</td>
<td>ER$^+$ and/or PR$^+$</td>
<td>3</td>
<td>pCR</td>
<td>13</td>
<td>Taxotere–AC</td>
</tr>
<tr>
<td>24</td>
<td>46</td>
<td>HER2$^+$</td>
<td>3</td>
<td>pCR</td>
<td>24</td>
<td>AC–concurent Taxol + trastuzumab</td>
</tr>
<tr>
<td>25</td>
<td>33</td>
<td>Triple negative</td>
<td>3</td>
<td>pCR</td>
<td>15</td>
<td>AC–weekly Taxol</td>
</tr>
<tr>
<td>26</td>
<td>39</td>
<td>HER2$^+$</td>
<td>2</td>
<td>pCR</td>
<td>14</td>
<td>Trastuzumab + Lapatinib</td>
</tr>
<tr>
<td>27</td>
<td>46</td>
<td>ER$^+$ and/or PR$^+$</td>
<td>3</td>
<td>pCR</td>
<td>13</td>
<td>AC–Taxol</td>
</tr>
<tr>
<td>28</td>
<td>42</td>
<td>Triple negative</td>
<td>3</td>
<td>pCR</td>
<td>15</td>
<td>Taxol + cisplatin ± everolimus</td>
</tr>
<tr>
<td>29</td>
<td>34</td>
<td>Triple negative</td>
<td>3</td>
<td>pCR</td>
<td>16</td>
<td>Taxotere–AC</td>
</tr>
<tr>
<td>30</td>
<td>44</td>
<td>HER2$^+$</td>
<td>3</td>
<td>pCR</td>
<td>7</td>
<td>Trastuzumab + Lapatinib</td>
</tr>
<tr>
<td>31</td>
<td>37</td>
<td>Triple negative</td>
<td>3</td>
<td>pCR</td>
<td>7</td>
<td>Taxol + cisplatin ± everolimus</td>
</tr>
<tr>
<td>32</td>
<td>39</td>
<td>Triple negative</td>
<td>3</td>
<td>pCR</td>
<td>14</td>
<td>AC–Taxol</td>
</tr>
<tr>
<td>33</td>
<td>48</td>
<td>HER2$^+$</td>
<td>3</td>
<td>pCR</td>
<td>29</td>
<td>Taxotere + carboplatin + Herceptin</td>
</tr>
</tbody>
</table>

---

and spectrally selective adiabatic inversion recovery fat saturation were implemented to reduce image artifacts. Subjects were breathing freely with no gating applied. The DW-MRIs consisted of 12 sagittal slices with slice thickness of 5 mm (no slice gap), TR = 3080 ms, TE = “shortest” (41 or 60 ms), Δ = 19.8 or 29 ms, and δ = 10.7 or 21.4. NSA = 10. The total scan time for THRIVE, DCE-MRI, and DW-MRI data was approximately 2.7, 6.7, and 4.7 minutes, respectively.
and transformed to estimates of tumor cell number using Eq. B (3, 4). A two-dimensional, mechanically coupled reaction-diffusion tumor model, Eqs. C–E, was used to describe tumor cell logistic growth/decay and diffusion based on the central slice of the MR data. This model incorporates a tumor growth "mass effect" where accumulated mechanical distortion energy has an inhibitory effect on tumor cell invasiveness (5). Tumor cellularity at baseline (t1) and after one cycle of neoadjuvant therapy (t2) was used to estimate the spatially varying proliferation rates and a global tumor cell diffusion parameter by a conjugate-gradient nonlinear optimization. Following parameter fitting, the model was projected forward in time (using the estimated proliferation and tumor cell diffusion parameters) to the final time point at the conclusion of neoadjuvant therapy (t3), and the tumor cellularity was calculated as a model prediction. A schematic of the model parameter estimation and prediction framework is shown in Fig. 1. In addition, the cellularity maps for each patient at each time point for both the experimentally observed (t1 and t2) and model predicted (t3) cellularity data were summed to yield an estimate of the total tumor cellularity. To eliminate volumetric bias, these numbers are expressed as a percent change relative to a reference time point; for example, a percent change in cellularity from t1 to t2 is defined as 100(t2 − t1)/t1.

Statistical analysis
Statistical analysis between non-pCR and pCR patient groups for percent changes in each analysis metric was performed using the Wilcoxon test. Statistical significance was set at P < 0.05.
Receiver operating characteristic (ROC) curves were generated for prediction of pCR for both the mechanically coupled model and a standard reaction–diffusion model. ROC curves were analyzed and area under the curve (AUC) and 95% confidence intervals (CI) were generated for each model. The optimal cutoff was selected utilizing the Youden index, which maximizes the difference between the true positive rate and the false positive rate (33). Data were analyzed using GraphPad Prism (GraphPad Software).

Results

Clinical patient data
Thirty-three patients (median age, 46; range, 28–67) completed scanning at t1 and at t2. The median time between t1 and t2 was 14 days (range, 7–29 days). Table 1 summarizes the salient features of the patient data set, including their tumor type and pathologic response. After neoadjuvant therapy, 12 of 33 patients (36%) were defined as having achieved pCR.

Representative imaging and modeling data
Imaging data and model predictions for tumors from two representative patients are shown in Figs. 2 and 3. Fig. 2 displays data from a patient that achieved pCR at the conclusion of neoadjuvant therapy that was scanned before, after the first cycle, and at the conclusion of neoadjuvant therapy in the form of near complete response. Figure 3 displays similar data for a representative patient with residual disease at the time of surgery.

Imaging data from a patient that achieved pCR at the conclusion of neoadjuvant therapy that was scanned before, after the first cycle, and at the conclusion of neoadjuvant therapy in the form of near complete response. Figure 3 displays similar data for a representative patient with residual disease at the time of surgery.
The estimated cellularity map for this patient exhibits an opposite trend from that of the pCR patient, with increasing estimated cellularity observations from $t_1$ to $t_2$. The mechanically coupled reaction–diffusion model prediction is then shown to predict a lack of response to therapy with an increase in cellularity at $t_3$. Compared to observed cellularity data, the model overpredicts cellularity at the final time point. Combined, representative images and associated estimated parameter maps of proliferation rates depict overall prediction of regression of disease for a responding patient and significant progression of disease for a nonresponding patient.

Predictive performance of analysis metrics

Table 2 reports the overall performance for predicting pCR from a group of 33 patients exhibiting a varying degree of responsiveness to neoadjuvant therapy for analysis metrics based on RECIST.
Biomechanical Model for Predicting Breast Cancer Response

Figure 3.
The model prediction for one representative patient not achieving pCR. Anatomical THRIVE images (A–C) and baseline DCE with ADC overlays (D–F) are shown for baseline (left column), after one cycle (middle column), and at the conclusion of neoadjuvant therapy (right column). Tumor cellularity is estimated (G–I) and used in conjunction with the mechanics coupled reaction–diffusion model to estimate key model parameters of tumor cell diffusion and proliferation (J) between the baseline and early imaging time points. Parameter estimates are then used in the model to predict tumor cellularity at the time of surgery (K) and compared to observation (I). The mechanics coupled reaction–diffusion model predicts a lack of response to neoadjuvant therapy, reflected by a significant increase in tumor burden, in agreement of pathologic determination of non-pCR at the time of surgery.

(i.e., measurement of tumor longest dimension), observed cellularity (based on ADC values from DW-MRI), reaction–diffusion model prediction, and mechanics coupled reaction–diffusion model prediction. Area under the receiver operating characteristic curve, sensitivity, and specificity are reported for each metric, along with 95% confidence intervals. Figure 4 depicts the average value, 95% confidence interval as indicated by error bars, and P value for comparisons between non-pCR and pCR tumors for each analysis metric, along with ROC curves.

Simple analysis of differences in tumor morphologic and cellularity observations before and after the first cycle of neoadjuvant therapy exhibit a modest ability to predict pCR status at the conclusion of therapy. The change in tumor longest dimension between imaging time points \( t_1 \) and \( t_2 \), based on RECIST criteria,
We previously introduced a novel mathematical framework for predictive modeling that is centered on integrating quantitative \textit{in vivo} imaging data with biomechanical models of tumor growth (9). This approach represents a significant departure from existing paradigms in mathematical oncology modeling by using patient-specific data to parameterize a model that can then be used to make a prediction at a future time point that can then be checked directly against patient response. In this work, we retrospectively apply this framework to a database of patients exhibiting varying degrees of responsiveness to neoadjuvant therapy. We compared model predictions of responsiveness to pathologic response assessment at the time of surgery. Our results demonstrate a significant predictive ability of our mechanics coupled modeling approach in identifying patients that would go on to achieve pCR, as indicated by a strong AUC of 0.87. Our mechanics coupled reaction–diffusion modeling approach significantly outperformed other, commonly used metrics, including analysis of tumor longest dimension (i.e., RECIST), early-cycle changes in DW-MRI (used as empirical input data to the models), and standard reaction–diffusion predictive modeling. Compared with the standard reaction–diffusion model, the mechanically coupled model exhibits significantly improved prediction specificity, reflected by improved prediction of true non-pCR patients (55% vs. 84%, respectively). Further analysis of the patients for which mechanically coupled modeling improved predictability over standard modeling (data not shown), failed to reveal correlations with any other known factor (including breast density, patient age, and breast cancer subtype, among others).

Our results also confirm previous reports of the use of early cycle DW-MRI ADC data alone in predicting neoadjuvant therapy response (34–39). Trends of decreasing/increasing cellularity are clearly visible between the observed cellularity before and after the first cycle of therapy, as shown in Figs. 2 and 3, with predictive AUC of 0.73. However, analysis of these data is seen to exhibit limited specificity, as has been previously demonstrated (35, 40).

The results from this study are promising, but we recognize that there are several limitations in our current approach. First, we estimate the key model parameters (i.e., proliferation and tumor cell diffusion) from data obtained before and after the first cycle of neoadjuvant therapy; this is an admittedly (temporally) sparse set of measurements for attempting to capture the dynamics through a model fitting procedure. In addition, we have assumed that reconstructed model parameters do not vary in time; this is essentially equivalent to assuming a constant antitumor effect during neoadjuvant therapy treatment and this is clearly a simplification of the response of tumor cells to neoadjuvant therapy. True response undoubtedly exhibits strong nonlinear temporal response to therapy; indeed, the evolution of a resistant phenotype in the presence of continued chemotherapeutic administration speaks directly to a nonlinear effect that is not currently taken into account in our approach. However, it is clinically infeasible to acquire sufficient imaging time points throughout the course of therapy to accurately predict the temporal changes in proliferation rates and tumor cell diffusion with the current model. We are currently exploring acquisition of one additional early imaging time point, collected after two cycles of therapy, in order to better understand the temporal evolution of parameters and more accurate prediction of response.

A second limitation, as also noted in Li and colleagues (17), is the variation in the breast cancer subtype, therapeutic regimen (including the specific therapeutic agent and dosing frequency), and number of days elapsed between imaging time points, \( t_1 \) and \( t_2 \). Thus, it is possible that the modeling approach could be influenced by the underlying dynamics and biology of specific breast cancer subtypes as well as the particular therapy regimen utilized. This source of uncertainty due to patient-specific biologic variability is particularly difficult to control, due to the nature of clinical research data acquisition constraints. It will be important, as a greater number of patients are analyzed with this methodology, to statistically analyze the model relative to cancer subtype, therapeutic regimen, and imaging time point delay to determine these effects. In addition, future work toward model validation in \textit{preclinical} and \textit{in vitro} systems will facilitate greater experimental control and provide further understanding toward model robustness in the presence of such biological variability. Of course, the encouraging preliminary results achieved with our modeling approach in spite of this variability points to the importance, and potential generalizability, of using models based on patient-specific information.

Another limitation is that our current approach utilizes \textit{central-slice} MR data to initialize and constrain two-dimensional mathematical models, rather than using full image volumes and three-dimensional models. We do note, however, that we are utilizing...
somewhat thick slices, 5 mm, due to the spatio-temporal acquisition requirements of the trial for which the MRI data were originally acquired. Extension of our approach to three-dimensional analysis is straightforward, and we would expect an enhanced predictive capability through the use of additional volumetric data. However, the current computational demands for iterative reconstruction of volumetric parameter maps significantly limit the feasibility of extending our approach to three-dimensional analysis for an entire patient database at this time. Currently, efforts are underway to refine our approach by exploring significant computational speed enhancements through the use of high-performance computing cluster and/or graphics processing unit processing in addition to algorithmic enhancements.

Figure 4.
Tumors from patients either achieving pCR or not were assessed as a percent change from \( t_1 \) to \( t_2 \) by RECIST criteria (A) and observed cellularity (B) and as a percent change from \( t_2 \) to predicted \( t_3 \) by reaction diffusion model prediction (C) and mechanics coupled model prediction (D). Data are expressed as mean with 95% confidence intervals, with \( P \) values indicated for statistically significant differences between groups. ROC curves for all analysis metrics are shown along with the dashed line of identity (E).
The mechanically coupled reaction diffusion model adds two additional degrees of freedom to each node in the finite element mesh (in addition to the existing degree of freedom for tumor cell number) due to the need for calculation of a displacement solution. This added complexity increases the computation time for the forward model by approximately 40%, without parallelization of matrix assembly and/or matrix inversion. In addition, the impact on total wall-clock time is relatively limited as the entire mechanically coupled reaction diffusion model prediction approach typically requires only 1 to 2 hours for each patient.

At present, our mechanics coupled approach relies on the use of literature values for the elastic properties of the breast (9). In addition, our approach currently ignores other important biologic factors beyond simple growth and mechano-inhibitory diffusion. Other ongoing efforts are designed to address these limitations through incorporation of additional quantitative patient-specific imaging methodologies to inform more complex models (13).

Given these limitations, we note that our approach compares very favorably, with similar AUC, to previous multimodal statistical regression analysis of this same patient population in previous work that combines ROI and voxel-level DW-MRI and DCE-MRI analysis (17). Importantly, our approach currently includes data from only one quantitative imaging source, DW-MRI. Contrast-enhanced MRI data are used in this work only to identify tumor ROI, with no sensitivity to pharmacokinetic parameters fit from dynamic DCE-MRI data. It is therefore very encouraging that our model-based analysis framework, based on unimodal and two-dimensional central-slice input data, achieves similar predictive results to multimodal full-volume analysis.

In summary, we have demonstrated a model-based analysis method that provides predictions of therapeutic response using patient-specific early time point imaging data within the course of therapy. The framework provides good agreement with pathologic response observations as demonstrated by a strong predictive ability. The results suggest that an imaging-driven biophysically constrained modeling approach that combines reaction-diffusion with mechanical effects is a predictive indicator of response to therapy. Future work will seek to further enhance the predictive capacity of our approach by expanding the mathematical model of tumor response to include model terms that can be populated with other sources of quantitative patient-specific noninvasive imaging, including DCE-MRI, fluorodeoxyglucose positron emission tomography (FDG-PET), and magnetic resonance elastography (MRE).

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: J.A. Weis, M.I. Miga, T.E. Yankeelov
Development of methodology: J.A. Weis, M.I. Miga, T.E. Yankeelov
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.A. Weis, L.R. Arlinghaus, V. Abramson, A.B. Chakravarthy, T.E. Yankeelov
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.A. Weis, X. Li, T.E. Yankeelov
Writing, review, and/or revision of the manuscript: J.A. Weis, M.I. Miga, L.R. Arlinghaus, X. Li, V. Abramson, A.B. Chakravarthy, T.E. Yankeelov
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.A. Weis, A.B. Chakravarthy, P. Pendyala
Study supervision: J.A. Weis, A.B. Chakravarthy, T.E. Yankeelov

Acknowledgments
The authors offer their sincerest appreciation to the women who volunteered to participate in this study. The authors thank the National Institutes of Health for funding through NCI U101CA142565, NCI U01CA174706, NCI R25CA092043, NCI IP50 098131, NCI P50CA68485, NCI R01CA138599, and NINDS ZR01NS049251. The authors also thank the Kleberg Foundation for generous support of the imaging program at Vanderbilt and the support provided by the Vanderbilt Initiative in Surgery and Engineering Pilot Award Program.

Grant Support
This work was supported by the National Institutes of Health: NCI U101CA142565, NCI U01CA174706, NCI R25CA092043, NCI IP50 098131, NCI P50CA68485, NCI R01CA138599, and NINDS ZR01NS049251. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 3, 2014; revised May 26, 2015; accepted July 29, 2015; published OnlineFirst September 2, 2015.

References
Biomechanical Model for Predicting Breast Cancer Response


Predicting the Response of Breast Cancer to Neoadjuvant Therapy Using a Mechanically Coupled Reaction–Diffusion Model

Jared A. Weis, Michael I. Miga, Lori R. Arlinghaus, et al.

Cancer Res 2015;75:4697-4707. Published OnlineFirst September 2, 2015.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-14-2945

Cited articles
This article cites 38 articles, 6 of which you can access for free at:
http://cancerres.aacrjournals.org/content/75/22/4697.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/75/22/4697.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/75/22/4697.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.